Alpine Immune Sciences
Market Cap
US$218.3m
Last Updated
2020/08/14 12:11 UTC
Data Sources
Company Financials +
Executive Summary
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 22.3% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has Alpine Immune Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALPN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-11.5%
ALPN
-1.2%
US Biotechs
0.5%
US Market
1 Year Return
97.7%
ALPN
32.7%
US Biotechs
18.7%
US Market
Return vs Industry: ALPN exceeded the US Biotechs industry which returned 32.7% over the past year.
Return vs Market: ALPN exceeded the US Market which returned 18.7% over the past year.
Shareholder returns
| ALPN | Industry | Market | |
|---|---|---|---|
| 7 Day | -11.5% | -1.2% | 0.5% |
| 30 Day | -0.2% | -5.5% | 4.9% |
| 90 Day | 187.0% | 3.8% | 19.8% |
| 1 Year | 97.7%97.7% | 34.7%32.7% | 21.2%18.7% |
| 3 Year | 16.3%16.3% | 34.8%28.4% | 46.2%36.8% |
| 5 Year | n/a | 12.4%4.4% | 85.3%65.1% |
Price Volatility Vs. Market
How volatile is Alpine Immune Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Is Alpine Immune Sciences' (NASDAQ:ALPN) 126% Share Price Increase Well Justified?2 months ago | Simply Wall St
Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway4 months ago | Simply Wall St
What You Must Know About Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Beta ValueValuation
Is Alpine Immune Sciences undervalued compared to its fair value and its price relative to the market?
10.73x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALPN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALPN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALPN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALPN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALPN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALPN is overvalued based on its PB Ratio (10.7x) compared to the US Biotechs industry average (3.4x).
Next Steps
Future Growth
How is Alpine Immune Sciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
-22.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALPN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALPN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALPN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALPN's revenue (27.2% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: ALPN's revenue (27.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALPN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Alpine Immune Sciences performed over the past 5 years?
-54.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALPN is currently unprofitable.
Growing Profit Margin: ALPN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALPN is unprofitable, and losses have increased over the past 5 years at a rate of 54% per year.
Accelerating Growth: Unable to compare ALPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALPN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.8%).
Return on Equity
High ROE: ALPN has a negative Return on Equity (-203.82%), as it is currently unprofitable.
Next Steps
Financial Health
How is Alpine Immune Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: ALPN's short term assets ($91.2M) exceed its short term liabilities ($28.2M).
Long Term Liabilities: ALPN's short term assets ($91.2M) exceed its long term liabilities ($58.3M).
Debt to Equity History and Analysis
Debt Level: ALPN is debt free.
Reducing Debt: ALPN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALPN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALPN has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 49.7% each year.
Next Steps
Dividend
What is Alpine Immune Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALPN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALPN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Mitch Gold (52 yo)
4.17yrs
Tenure
US$1,555,931
Compensation
Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the ...
CEO Compensation Analysis
Compensation vs Market: Mitch's total compensation ($USD1.56M) is about average for companies of similar size in the US market ($USD1.27M).
Compensation vs Earnings: Mitch's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 4.17yrs | US$1.56m | 0.11% $ 247.0k | |
| President and Head of Research & Development | 1.33yrs | US$970.59k | 0.051% $ 112.1k | |
| Senior VP | 3.33yrs | US$809.55k | no data | |
| Chief Technology Officer | 1.17yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.58yrs | no data | no data | |
| Senior Vice President of Business Development & Corporate Strategy | 0.58yr | no data | no data |
1.5yrs
Average Tenure
52yo
Average Age
Experienced Management: ALPN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 4.17yrs | US$1.56m | 0.11% $ 247.0k | |
| Independent Director | 3.08yrs | US$78.01k | 0.063% $ 138.0k | |
| Independent Director | 3.08yrs | US$72.64k | no data | |
| Independent Director | 4.17yrs | US$69.26k | no data | |
| Independent Director | 4.17yrs | US$71.76k | no data | |
| Member of Scientific Advisory Board | 1.75yrs | no data | no data | |
| Non-Employee Director | 4.17yrs | US$59.26k | 0.25% $ 542.9k | |
| Scientific Advisory Board Chairman | no data | no data | no data | |
| Independent Director | 2.33yrs | US$66.76k | no data | |
| Member of Scientific Advisory Board | 1.75yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.1yrs
Average Tenure
58yo
Average Age
Experienced Board: ALPN's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.7%.
Top Shareholders
Company Information
Alpine Immune Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Alpine Immune Sciences, Inc.
- Ticker: ALPN
- Exchange: NasdaqGM
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$218.293m
- Shares outstanding: 23.73m
- Website: https://www.alpineimmunesciences.com
Number of Employees
Location
- Alpine Immune Sciences, Inc.
- 201 Elliott Avenue West
- Suite 230
- Seattle
- Washington
- 98119
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 34LA | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2017 |
| ALPN | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jul 2017 |
Biography
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/14 12:11 |
| End of Day Share Price | 2020/08/13 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.